Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Intranasal Antibody Gene Transfer in Mice and Ferrets Protects Against Influenza Infection

By BiotechDaily International staff writers
Posted on 13 Jun 2013
Image
Image
Image: Senior author Dr. James M. Wilson (Photo courtesy of the University of Pennsylvania).
Image: Senior author Dr. James M. Wilson (Photo courtesy of the University of Pennsylvania).
Transmission of the influenza virus was blocked in animal models by a gene therapy technique that introduced a neutralizing antibody gene directly into the cells lining the nose and respiratory system.

Investigators at the University of Pennsylvania (Philadelphia, USA) worked with mouse and ferret influenza models. To protect these animals against influenza A infection the investigators used a modified adeno-associated virus (AAV) vector to deliver the gene that encodes the broadly neutralizing monoclonal anti-influenza antibody FI6 directly into the nasopharyngeal mucosa of the mice and ferrets.

Test animals were exposed to lethal quantities of three strains of influenza serotype H5N1 and two strains of serotype H1N1, all of which were associated with historic human pandemics (including the H1N1 1918 "Spanish flu" pandemic).

The investigators reported in the May 29, 2013, online edition of the journal Science Translational Medicine that intranasal delivery of the FI6 gene afforded complete protection against influenza infection in both the mouse and ferret model systems.

“The experiments described in our paper provide critical proof-of-concept in animals about a technology platform that can be deployed in the setting of virtually any pandemic or biological attack for which a neutralizing antibody exists or can be easily isolated,” said senior author Dr. James. M. Wilson, professor of pathology and laboratory medicine at the University of Pennsylvania. “Further development of this approach for pandemic flu has taken on more urgency in light of the spreading infection in China of the lethal bird strain of H7N9 virus in humans.”


Related Links:
University of Pennsylvania



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.